米维沙班联合抗血小板治疗用于急性冠脉综合征事件后
该Ⅲ期随机安慰剂对照试验在急性冠脉综合征事件后7天内、标准抗血小板治疗基础上加用口服米维沙班25 mg每日两次,计划期中分析基于556个判定终点后因无效提前终止。共纳入14,194例患者,中位随访12.2个月,主要疗效终点(心血管死亡、心梗或缺血性卒中)米维沙班组5.4% vs 安慰剂组5.1%(HR 1.05,95%CI 0.91–1.21,P=0.50),BARC 3c或5型出血0.3% vs 0.3%(P=0.88)。结论:米维沙班未降低缺血事件风险,也未增加颅内或致命性出血。
要点
- 急性冠脉综合征后7天内、标准抗血小板治疗基础上加用米维沙班25 mg口服每日两次,主要疗效终点无获益(HR 1.05,95%CI 0.91–1.21,P=0.50)。
- 主要安全终点BARC 3c或5型出血(颅内或眼内出血影响视力或致命性出血)两组均为0.3%(P=0.88),未增加严重出血。
- 试验因无效提前终止:计划期中分析基于556个判定疗效终点后终止。
- 共纳入14,194例患者(米维沙班7094例,安慰剂7100例),中位随访12.2个月。
- 主要疗效终点事件:米维沙班组384例(5.4%),安慰剂组365例(5.1%)。
适用人群与场景
- 急性冠脉综合征事件后7天内的患者,在标准抗血小板治疗基础上加用研究药物。
诊断标准与关键阈值
- 主要疗效终点:心血管死亡、心肌梗死或缺血性卒中的复合终点,采用时间-事件分析。
- 主要安全终点:BARC 3c或5型出血(颅内或眼内出血影响视力或致命性出血)。
处置流程与药物剂量
- 急性冠脉综合征事件后7天内,在标准抗血小板治疗基础上加用口服米维沙班25 mg每日两次或匹配安慰剂。
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- Ⅲ期随机、安慰剂对照试验,共纳入14,194例患者(米维沙班7094例,安慰剂7100例),中位随访12.2个月。
- 主要疗效终点事件:米维沙班组384例(5.4%),安慰剂组365例(5.1%),HR 1.05(95%CI 0.91–1.21),P=0.50。
- BARC 3c或5型出血:米维沙班组23例(0.3%),安慰剂组22例(0.3%),P=0.88。
- 计划期中分析基于556个判定疗效终点后,试验因无效提前终止。
证据类型、等级与局限
- 证据类型:Ⅲ期随机、安慰剂对照试验。
- 局限:因无效提前终止;原文未提及其他局限。
对床旁实践的改变
- 急性冠脉综合征后7天内、标准抗血小板治疗基础上加用米维沙班25 mg每日两次不降低心血管死亡、心梗或缺血性卒中风险,不应基于本试验常规使用。
- 该方案未增加颅内或致命性出血,但主要疗效终点无获益且试验因无效终止。
- 原文未提及适用与不适用人群的进一步区分或常见陷阱。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Patients are at increased risk for recurrent ischemic events after an acute coronary syndrome event. Milvexian, an oral factor XIa inhibitor, may reduce the risk of major adverse clinical events with minimal bleeding risk.
METHODS: In this phase 3, randomized, placebo-controlled trial, we evaluated the efficacy and safety of milvexian when added to standard antiplatelet therapy within 7 days after an acute coronary syndrome event. Patients were assigned in a 1:1 ratio to receive oral milvexian (25 mg twice daily) or matched placebo. The primary efficacy outcome was a composite of cardiovascular death, myocardial infarction, or ischemic stroke as evaluated in a time-to-event analysis. The principal safety outcome was Bleeding Academic Research Consortium (BARC) type 3c or 5 bleeding (intracranial or intraocular bleeding that compromises vision or fatal bleeding).
RESULTS: After a planned interim analysis that was based on 556 adjudicated efficacy end points, the trial was terminated for futility. A total of 14,194 patients had been enrolled, with 7094 assigned to receive milvexian and 7100 to receive placebo. After a median follow-up of 12.2 months, a primary efficacy outcome event had occurred in 384 patients (5.4%) in the milvexian group and in 365 patients (5.1%) in the placebo group (hazard ratio, 1.05; 95% confidence interval, 0.91 to 1.21; P = 0.50). BARC type 3c or 5 bleeding occurred in 23 patients (0.3%) in the milvexian group and in 22 patients (0.3%) in the placebo group (P = 0.88).
CONCLUSIONS: Among patients with a recent acute coronary syndrome event, milvexian did not decrease the risk of cardiovascular death, myocardial infarction, or ischemic stroke but did not increase the risk of intracranial or fatal bleeding, as compared with placebo. (Funded by Janssen Research and Development and Bristol Myers Squibb; LIBREXIA ACS ClinicalTrials.gov number, NCT05754957.).
参考来源
- Gibson CM, Steg PG, Bahit MC, et al. Milvexian with Antiplatelet Therapy after Acute Coronary Syndrome Event. N Engl J Med. 2026. PMID: 42670965. doi:10.1056/NEJMoa2608717
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。